Objective: To observe the efficacy and safety of
re-irradiation for recurrent malignant tumor. Methods: Eighteen patients with recurrent malignant tumor were enrolled,
in whom eight patients with esophageal cancer, five with nasopharyngeal cancer,
two with spinal bone metastases, one with rectal cancer, one with cervical
cancer and one with cerebral glioma. The total dose of GTV was 30 - 50 Gy with
2 - 3 Gy per fraction. Results: Median follow-up time was ten months (range 3 - 42 months). For the sixteen
evaluable patients, eight patients had a complete response, five patientshad a partial response, one patient had a
stable disease, one patient did not receive the evaluation, the symptoms
persisted for the last one after radiotherapy, and the time toprogression was 5 - 34 months. Radiotherapy
also brought considerablerelief of pain in both patients with spinal bone metastases. Toxicity
was generally tolerable and manageable. Conclusions: For the patients with recurrent tumor, re-irradiation was effective and
Y. S. Kim, C. G. Lee, K. H. Kim, et al. Re-irradiation of recur- rent esophageal cancer after primary definitive radiotherapy. Radiation Oncology Journal, 2012, 30(4): 182-188.
S. Lutz, L. Berk, E. Chang, et al. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Interna- tional Journal of Radiation Oncology Biology Physics, 2011, 79(4): 965-976.